Hair Loss Market to Hit $16B by 2030: New Treatments & Korean Companies Leading the Way
The global market for hair loss treatments is experiencing significant growth, fueled by a rise in younger individuals seeking solutions. As of February 15, 2026, the market is projected to reach $160 billion (approximately 23 trillion Korean Won) by 2030, growing at an annual rate of 8.7% from last year. Pharmaceutical interventions currently dominate treatment approaches, accounting for 98.8% of all therapies.
Rising Demand and Innovative Approaches
Currently, approximately 147 million people worldwide are affected by alopecia areata. With an increasing number of younger patients experiencing hair loss – with 40% of men experiencing some degree of hair loss by age 35 – pharmaceutical companies are intensifying their research and development efforts.
New Therapies in Development
Several companies are making strides in developing novel treatments. Cosmo Pharmaceuticals, an Italian firm, demonstrated promising results in Phase 3 clinical trials for ‘Clascoterone’ 5% solution, a new treatment for male pattern baldness. The treatment, applied topically, increased hair count by up to five times compared to a placebo in a study of 1465 men across 50 locations in the US and Europe. It works by blocking the binding of dihydrotestosterone (DHT) – a hormone contributing to hair loss – to receptors on the scalp, potentially reducing systemic side effects.
Pelage Pharma, a US-based company, is preparing to enter Phase 3 clinical trials for ‘PP405’, a hair loss treatment utilizing stem cell technology. Positive results were observed in a Phase 2a clinical trial targeting androgenetic alopecia. The company recently secured $120 million in Series B funding led by Arch Venture Partners and Google Ventures.
Veradermics, also based in the US, is developing ‘VDPHL01’, an extended-release oral formulation of minoxidil, a medication known to expand scalp blood vessels and promote hair growth. This aims to improve patient convenience compared to existing topical minoxidil products.
Domestic Efforts and Future Outlook
South Korean companies are also actively involved in hair loss treatment research. JW Pharmaceutical’s ‘JW0061’ is a novel drug candidate that directly binds to the GFRA1 receptor on hair follicle stem cells, stimulating hair growth. This differs from existing treatments that rely on hormone suppression or vasodilation. The company received approval to begin Phase 1 clinical trials this month and has secured a US patent for the technology.
Olik is conducting a Phase 1b/2a trial in Australia for ‘OLX104C’, which reduces the expression of androgen receptors – a key factor in androgenetic alopecia – to block hormone-driven hair loss.
Chong Kun Dang is developing ‘CKD-843’, a dutasteride-based injectable hair loss treatment currently in Phase 3 clinical trials. PromBio is securing pre-clinical safety data for its stem cell-based hair loss treatment candidate, paving the way for clinical trials.
The hair loss treatment market in South Korea is expected to continue growing, supported by government policies. President Lee Jae-myung has indicated that addressing hair loss is a matter of “survival” and has directed the Ministry of Health and Welfare to consider expanding health insurance coverage for hair loss treatments.
Frequently Asked Questions
What is the projected size of the global hair loss market by 2030?
The global hair loss market is projected to reach $160 billion (approximately 23 trillion Korean Won) by 2030.
What percentage of hair loss treatments are pharmaceutical interventions?
Pharmaceutical interventions currently account for 98.8% of all hair loss treatments.
Which company has demonstrated promising results in Phase 3 clinical trials for a new hair loss treatment?
Cosmo Pharmaceuticals has demonstrated promising results in Phase 3 clinical trials for ‘Clascoterone’ 5% solution, a new treatment for male pattern baldness.
As research continues and potential new treatments emerge, what impact will increased access to these therapies have on individuals experiencing hair loss?